<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357964</url>
  </required_header>
  <id_info>
    <org_study_id>ENDA-025-17S-1</org_study_id>
    <secondary_id>1IK2CX001678</secondary_id>
    <nct_id>NCT04357964</nct_id>
  </id_info>
  <brief_title>Beige Fat, Energy, and the Natriuretic Peptide System</brief_title>
  <official_title>Beige Fat, Energy, and the Natriuretic Peptide System (ENDA-025-17S)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obese individuals experience an increased risk of cardiovascular and metabolic diseases.
      Evidence from genetic studies indicate that the natriuretic peptide (NP) system may protect
      against these diseases. NP levels differ by obesity status and race has not been established
      in humans. Thus, the investigators propose a study in which will quantify adipose tissue gene
      expression and energy expenditure in states of NP deficiency in humans. The overarching
      postulate is that obese and black individuals have NP deficiencies that contribute to less
      beige adipose tissue and lower energy expenditure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity represents a serious public health burden. Obese individuals experience increased
      risk of cardiovascular and metabolic cardiometabolic disease, including insulin diabetes,
      resistance, hypertension, and dyslipidemia. Obesity and obesity-associated cardiometabolic
      dysfunction are significant contributors to morbidity and mortality in Veterans. This
      indicates that obesity and cardiometabolic dysfunction are complex and multifactorial, and
      suggests that there are additional factors that contribute to the pathogenesis of obesity and
      its associated cardiometabolic risk that have been discovered. Moreover, some of the
      pharmacologic therapies for obesity can have adverse cardiovascular effects. Thus, it is
      crucial to improve the understanding of the multiple pathways contributing to the
      pathogenesis of obesity and obesity-associated cardiometabolic risk, including the
      identification of novel relevant pathways, in order to develop more effective treatments for
      these diseases. The proposed work will form a foundation for future high-impact studies of
      mechanisms for adiposity and cardiometabolic disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>adipose tissue gene expression of UCP1 (Uncoupling Protein 1)- differences by obesity status</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Primary endpoint is adipose tissue gene expression of UCP1 (Uncoupling Protein 1)- differences by obesity status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associations of adipose tissue gene expression of UCP1 with natriuretic peptide markers</measure>
    <time_frame>Study Day 1</time_frame>
    <description>The investigators will determine associations of adipose tissue gene expression of UCP1 with natriuretic peptide markers (natriuretic peptide receptor gene expression in adipose tissue, and circulating natriuretic peptide levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose tissue gene expression of UCP1 (Uncoupling Protein 1)- differences by race</measure>
    <time_frame>Study Day 1</time_frame>
    <description>The investigators will determine adipose tissue gene expression of UCP1 (Uncoupling Protein 1), and analyze differences by race (blacks compared with whites).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>obese and lean individuals</arm_group_label>
    <description>obese and lean individuals</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, and fat biopsy samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers who are U.S. veterans
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18-55 years

          -  Body Mass Index (BMI) &gt;= 18.5 and &lt;25 kg/m2 (lean), or BMI 30 kg/m2 (obese)

        Exclusion Criteria:

          -  Significant pulmonary, liver, or renal disease

          -  Heart failure (any type) or unstable coronary artery disease

          -  Diabetes Mellitus (Types 1 and 2)

          -  Thyroid dysfunction

          -  Active malignancy

          -  Chronic inflammatory diseases, such as inflammatory bowel disease, hepatitis,
             rheumatoid arthritis

          -  Postmenopausal status (for women)

          -  Current use of medications likely to affect energy homeostasis, including
             glucocorticoids, amphetamines, and beta blockers

          -  Currently pregnant or breastfeeding, or unwilling to avoid becoming pregnant or
             breastfeeding during study duration

          -  Significant claustrophobia that would prevent the use of the metabolic cart as part of
             the study protocol

          -  Hemoglobin A1c (HbA1c) &gt;= 6.5%

          -  Liver Function Tests (LFTs) elevated &gt;3x upper limit of normal

          -  Estimated Glomerular Filtration Rate (eGFR) &lt;40 ml/min

          -  Currently abnormal thyroid stimulating hormone (TSH)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Neubecker Bachmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tennessee Valley Healthcare System Nashville Campus, Nashville, TN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ezelle McDonald, PhD</last_name>
    <phone>(615) 873-8694</phone>
    <phone_ext>68694</phone_ext>
    <email>Ezelle.McDonald@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy A Mambungu, LPN</last_name>
    <phone>(615) 343-5828</phone>
    <email>Cindy.Mambungu@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tennessee Valley Healthcare System Nashville Campus, Nashville, TN</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-2637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Reynolds, BS</last_name>
      <phone>(615) 875-9854</phone>
      <email>cassandra.f.reynolds@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Katherine N Bachmann, MD</last_name>
      <email>Katherine.n.bachmann@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine Neubecker Bachmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ezelle McDonald, PhD</last_name>
      <phone>615-875-6520</phone>
      <email>ezelle.t.mcdonald@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Mambungu, LPN</last_name>
      <phone>6153435828</phone>
      <email>cindy.a.booker@vumc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adipose tissue</keyword>
  <keyword>beige adipose tissue</keyword>
  <keyword>cardiovascular physiology</keyword>
  <keyword>B-type natriuretic peptide</keyword>
  <keyword>metabolism</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

